GSK-572
belongs to a class of anti-HIV drugs called Integrase Inhibitors. For a description of the life-cycle of the AIDS virus, and the targets of each class of drugs, click here.
GSK-572 is marketed by ViiV Healthcare in collaboration with Shionogi & Co.
Our quick-reference chart allows you to compare all the currently available anti-HIV drugs, including dosing, side effects, & dietary restrictions.
Treatment News
Search for recent news and archived stories about
GSK-572.
Have more questions? Then post a question or comment in our Community Forums.
Check My Meds allows you to take the preventive step of determining whether the drugs you are taking interact with each other, or interact with a certain food, and cause a bad reaction in your body.
Our Lessons: Check out our informative Lessons covering various topics to help you make treatment decisions.
For a list of great books about living with HIV and making informed treatment decisions, along with easy links to buy them from Amazon.com, click here.
For a list of magazines, including POZ, the nation's leading magazine covering HIV and AIDS, click here.
GSK-572 (S/GSK1349572)
Pronunciation(s):
What is GSK-572?
GSK-572, formally S/GSK 1249572, is an experimental integrase inhibitor being developed by ViiV Healthcare in collaboration with Japan-based Shionogi & Co.
After HIV's genetic material is deposited inside a cell, its RNA must be converted (reverse transcribed) into DNA. A viral enzyme called integrase then helps to hide HIV's DNA inside the cell's DNA. Once this happens, the cell can begin producing genetic material for new viruses. Integrase inhibitors, such as GSK-572, are designed to block the activity of the integrase enzyme and to prevent HIV DNA from entering healthy cell DNA.
GSK-572 will need to be used in combination with other drugs. Clinical trials will evaluate its effect in combination with other drugs, including those currently approved for the treatment of HIV.
What is already known about GSK-572?
The GSK-572 dose has not been determined. However, early clinical trial results suggest that it can be used once daily—either with or without food—and without the use of a boosting agent, such as low-dose Norvir (ritonavir).
GSK-572 might interact with other medications, including those used to treat HIV. It is important that your personal physician and/or the research nurse or study investigator be aware of all drugs you are taking, including those you buy without a prescription.
GSK-572 holds promise for HIV-positive patients who are either starting HIV treatment for the first time or have used other HIV drugs in the past. It is unclear how well GSK-572 will work for people who have developed HIV resistance to the approved integrase inhibitor Isentress (raltegravir) or the experimental integrase inhibitor elvitegravir.
A small ten-day clinical trial of GSK-572, involving HIV-positive people who had not yet used an integrase inhibitor. Three doses of GSK-572 were evaluated: 2 mg, 10 mg or 50 mg, all taken once a day. The majority of patients taking GSK-572 for 10 days were able to decrease their viral loads to below 400 copies. This occurred in about 56 percent of those in the 2 mg and 10 mg groups, whereas it was documented in 90 percent of those in the 50 mg dosing group. In the 50 mg group, 70 percent got their viral loads below 50 copies.
What about drug interactions?
Studies on potential interactions between GSK-572 and other drugs have not yet been reported, but are planned and ongoing.
What is known about side effects?
Very little is known about the side effects of GSK-572. In the ten-day study completed thus far, only headache was found to be a possible side effect of GSK-572. No severe side effects were reported, and no volunteers withdrew from the study because of a side effect.
Additional studies evaluating the short- and long-term safety of GSK-572 are planned and ongoing.
Who should not take GSK-572?
It is not known whether GSK-572 will harm an unborn baby. It is very important to treat HIV/AIDS during pregnancy to reduce the risk of infecting your baby. Talk to your doctor about your treatment options.
It is not known whether GSK-572 passes into breast milk and what effect it may have on a nursing baby. To prevent transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed.
Where can I learn more about clinical trials of GSK-572?
If you would like to find out if you are eligible for any clinical trials that include GSK-572, there is an interactive web site run by ACRIA, the AIDS Community Research Initiative of America.
Another useful service for finding clinical trials is AIDSinfo.nih.gov, a site run by the U.S. National Institutes of Health. They have "health information specialists" you can talk to at their toll-free number at 1-800-HIV-0440 (1-800-448-0440).
Last Revised: December 03, 2009
This content is written by the editorial team at AIDSmeds.com.
Please find profiles of this team on our "About Us" page.
GSK-572
belongs to a class of anti-HIV drugs called 
Check My Meds
GSK-572 might interact with other medications, including those used to treat HIV. It is important that your personal physician and/or the research nurse or study investigator be aware of all drugs you are taking, including those you buy without a prescription.
It is not known whether GSK-572 will harm an unborn baby. It is very important to treat HIV/AIDS during pregnancy to reduce the risk of infecting your baby. Talk to your doctor about your treatment options.
It is not known whether GSK-572 passes into breast milk and what effect it may have on a nursing baby. To prevent transmission of the virus to uninfected babies, it is recommended that HIV-positive mothers not breast-feed.